Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction

Abstract Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20–30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E)-stained pathological slides are used for routine diagnosis of cancer type, they may also con...

Full description

Bibliographic Details
Published in:	npj Precision Oncology
Main Authors:	Oz Kilim, Alex Olar, András Biricz, Lilla Madaras, Péter Pollner, Zoltán Szállási, Zsofia Sztupinszki, István Csabai
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-01-01
Online Access:	https://doi.org/10.1038/s41698-025-00808-w

Similar Items

Automated prediction of COVID-19 severity upon admission by chest X-ray images and clinical metadata aiming at accuracy and explainability
by: Alex Olar, et al.
Published: (2023-03-01)

Physical imaging parameter variation drives domain shift
by: Oz Kilim, et al.
Published: (2022-12-01)

Deep-learning-based breast cancer stage prediction from H&E-stained whole-slide images in resource-constrained settings
by: Zsolt Bedőházi, et al.
Published: (2026-04-01)

Polymerase theta expression is correlated with proliferative capacity but not with DNA repair deficiency status in solid tumors
by: Zsofia Sztupinszki, et al.
Published: (2025-06-01)

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
by: Kun-Hsing Yu, et al.
Published: (2020-08-01)

Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
by: Zoltan Szallasi, et al.
Published: (2024-12-01)

Biomarkers of platinum resistance in serous ovarian cancer
by: A. Rybin
Published: (2025-09-01)

Annotated dataset for training deep learning models to detect astrocytes in human brain tissue
by: Alex Olar, et al.
Published: (2024-01-01)

SARS-CoV-2 receptor-binding domain deep mutational AlphaFold2 structures
by: Oz Kilim, et al.
Published: (2023-03-01)

Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
by: Byungsoo Ahn, et al.
Published: (2024-05-01)

Impact Evaluation of Score Classes and Annotation Regions in Deep Learning-Based Dairy Cow Body Condition Prediction
by: Sára Ágnes Nagy, et al.
Published: (2023-01-01)

Modern strategies of platinum resistance overcoming in patients with the serous ovarian cancer
by: Andriy Rybin
Published: (2018-11-01)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
by: Marco Donia, et al.
Published: (2023-08-01)

Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019-07-01)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
by: Daniela Criscuolo, et al.
Published: (2022-08-01)

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
by: Michelle Greenman, et al.
Published: (2024-08-01)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
by: Reem Abdallah, et al.
Published: (2023-06-01)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2019-12-01)

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
by: Miklos Diossy, et al.
Published: (2021-06-01)

Immunohistochemical parameters of serous ovarian carcinomas and possible mechanism of development of resistance to platinum-based drugs
by: G. V. Zhukova, et al.
Published: (2024-09-01)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
by: Nicholas Cardillo, et al.
Published: (2022-10-01)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2020-03-01)

Investigating the diversity of intratumoral microbiota in high-grade serous ovarian cancer with varying platinum sensitivity
by: Xianzhong Cheng, et al.
Published: (2026-06-01)

Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer
by: Kazuhiro Suzuki, et al.
Published: (2024-11-01)

Platinum-based chemotherapy promotes antigen presenting potential in monocytes of patients with high-grade serous ovarian carcinoma
by: Irina Larionova, et al.
Published: (2024-09-01)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
by: Claudia Winkler, et al.
Published: (2021-10-01)

Biologically informed deep learning for explainable epigenetic clocks
by: Aurel Prosz, et al.
Published: (2024-01-01)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
by: Kasia M. Dillon, et al.
Published: (2022-06-01)

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
by: Robert L. Hollis, et al.
Published: (2023-05-01)

The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy
by: T. A. Bogush, et al.
Published: (2020-05-01)

RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer
by: Sarah J. Taylor, et al.
Published: (2024-04-01)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
by: Jeyshka M. Reyes-Gonzalez, et al.
Published: (2019-03-01)

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
by: Tushar Tomar, et al.
Published: (2017-06-01)

Tumor Small Extracellular Vesicle‐Transmitted LncRNA CATED Promotes Platinum‐Resistance in High‐Grade Serous Ovarian Cancer
by: Yi Liu, et al.
Published: (2025-08-01)

Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI
by: Inye Na, et al.
Published: (2024-01-01)

Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
by: Janisha Silva Raju, et al.
Published: (2021-03-01)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
by: Yongmei Li, et al.
Published: (2022-03-01)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
by: Yuan Li, et al.
Published: (2021-03-01)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
by: Zheng Feng, et al.
Published: (2023-03-01)

Proteomic analysis reveals potential biomarker candidates in serous ovarian tumors – a preliminary study
by: Shona Pedersen, et al.
Published: (2025-04-01)